Implementation issues in disease management programs: a pharmaceutical company perspective.

Abstract

Eli Lilly, a pharmaceutical manufacturer, recently established a disease management subsidiary. The author, one of the key forces behind the new venture, provides a how-to based on the company's experiences in developing Integrated Disease Management, Inc. His views, from the pharmaceutical company perspective, may also be applicable to any organization seeking to climb into the red-hot arena of disease management.

Cite this paper

@article{Browne1995ImplementationII, title={Implementation issues in disease management programs: a pharmaceutical company perspective.}, author={R. Browne}, journal={Medical interface}, year={1995}, volume={8 4}, pages={60-5, 69} }